Partnerships with Industry
We invite industry to partner with us in fostering medical innovation in the areas of oncology, autoimmunity and transplantation medicine. Current industrial partners include:
Together with Miltenyi Biotec, the LIT is developing a cGMP-compliant, semi-automated manufacturing platform for the generation of CD22/CD19-bispecific CD8+ Tscm cells. The cellular product developed will be tested in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Together with Poseida Therapeutics, the LIT is developing a manufacturing platform for the generation of NY-ESO-1-TCR-redirected Tscm cells, functionally empowered through the overexpression of human miR-155 SNP rs377265631. The cellular product developed will be tested in patients with relapsed or refractory sarcoma.